Vijay Kasturi

[CG Oncology, Inc. @cgoncology]

For #NationalCancerSurvivorMonth, we honor the strength and resilience of cancer survivors everywhere.
For many patients with bladder cancer, survivorship is an ongoing journey—marked by the risk of recurrence and the anxiety of what comes next.
At CG Oncology, we’re committed to advancing bladder-sparing treatment candidates like cretostimogene, so patients have better options and more hope for the future.

[Vijay Kasturi @oncdoc67]

@FOXSports @USMNT He has2!!!!!!

[Vijay Kasturi @oncdoc67]

@adamfeuerstein I am in your corner as a very disappointed Spurs fan!

[CG Oncology, Inc. @cgoncology]

We’re honored to contribute to today's conversation at the 2026 ASCO Genitourinary (GU) Cancers Symposium with five posters featuring cretostimogene across the Non-Muscle Invasive Bladder Cancer (NMIBC) landscape.

View the posters here: https://t.co/YNlEA3HYPT

#BladderCancer #Urology #UroOncology

[Vijay Kasturi @oncdoc67]

@LauraBukavinaMD @apolo_andrea @UroOnc @hjwang26 @IBCG_BladderCA @CleClinicUro Missing an important trial: BOND-003 in BCG-Unresponsive which showed landmark 24 month CR of 42% at AUA

[OncLive.com @OncLive]

Today Colin Dinney, MD, of @MDAndersonNews shared some exclusive insights on updated data from the BOND-003 and CORE-001 trials of cretostimogene grenadenorepvec in BCG-unresponsive NMIBC! Check back at https://t.co/E5LOd0oiTe to learn more! @AmerUrological #AUA25 #blcsm

[CG Oncology, Inc. @cgoncology]

There were ~83,000 new cases of #bladdercancer in the U.S. in 2024.

Our investigational drug, cretostimogene grenadenorepvec, is designed to treat patients with BCG-unresponsive #NMIBC – which represents 75% of all new bladder cancer cases.

Learn more: https://t.co/H30Zzd2uIR

[CG Oncology, Inc. @cgoncology]

We're pleased to announce @CGOncology's Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. https://t.co/cA9lMKmiUl

[Zach Klaassen @zklaassen_md]

#ASCO24 CORE-001: Ph 2, single arm study of Creto + Pembro in BCG-UR, NMIBC w/ CIS @UrogerliMD @urotoday @cgoncology

⚡️n=35
⚡️CR rate 12 mo: 57.1%
⚡️CR rate 24 mo: 54.3%
⚡️CR rate any time: 82.9%
⚡️95.1% of CRs @ 12 mo remain in CR @ 24 mo
⚡️12 mo landmark RFS: 77.3%
⚡️24 mo landmark RFS: 69.6%
⚡️100% PFS, no progression to MIBC or mUC
⚡️12 mo landmark DoR: 81.6%
⚡️24 mo landmark DoR: 77.3%

[Vignesh Packiam, MD @VigneshPackiam]

Great results from this combination! The best benefit (to risk) from systemic checkpoint inhibition I have seen yet for NMIBC

[Nature Medicine @NatureMedicine]

Today at #ASCO24: In a phase 2 trial evaluating intravesical delivery of an oncolytic adenovirus + anti-PD-1 in patients with BCG unresponsive, non-muscle invasive #BladderCancer, the complete response rate at 12 months was 57.1% @UrogerliMD https://t.co/9TDJDVKyt6

[CG Oncology, Inc. @cgoncology]

🏙 Heading to #ASCO24? Our #patientcentric approach addresses all stages of #bladdercancer w/innovative #immunotherapies. Hear the final results of our CORE-001 Phase 2 trial, showcasing our commitment to improving patient outcomes & transforming care.

🔗 https://t.co/2BgAO9IhYF

[Vijay Kasturi @oncdoc67]

@worcesterpublic Any thoughts about a 2hr delay tomorrow ( Wednesday) am? It’s icy out there

[Vijay Kasturi @oncdoc67]

@LauraBukavinaMD @UrogerliMD Hi Laura. This is the wrong pictograph for the Core-001 study you are quoting. It shows results for the Bond-002 phase 2 study of Cretostimogene. Not the Core-001 study presented by Roger Li at AUA

[CG Oncology, Inc. @cgoncology]

Excited to announce we have received both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive #BladderCancer

Read the full release:

https://t.co/2wVFxzDUXg

[Roger Li @UrogerliMD]

The opening salvo delivered by @MarkTysonMD

[Vijay Kasturi @oncdoc67]

@jackiebrown_MD @VikramNarayan @WinshipAtEmory @emory_urology Congratulations Vikram!

[Vijay Kasturi @oncdoc67]

@UMassFootball Need to fire the Defensive Coordinator. Trying to change the entire defensive personnel on 2nd down when your opponent is playing hurry up offense is a brainless move! Doing it repeatedly is just plain stupid!!!

[Vijay Kasturi @oncdoc67]

@montypal @DUALIPA @eltonofficial Happy Fathers Day Monty!

[Vijay Kasturi @oncdoc67]

@DrChoueiri @FOXSoccer @Martin_AngelMD @fedelosco @FAndreMD @cdanicas @zmansour75 @ReneeSaliby @KarlSemaan @marc_eid Ticket prices for InterMiami games this year have already increased by 3-10X.